Founded in 1993
  Year: 2013 | Volume: 21 | Issue: 3-4 | Pages: 146-150
  Special Article
Branislava Ilincic, Zoran Stošic, Velibor Cabarkapa, Radmila Žeravica, Romana Mijovic
  Peptide receptor radiation therapy (PRRT) with radiolabeled octreotide analogs is effective treatment in patients with somatostatin receptor-positive neuroendocrine tumors. The kidneys are critical organ during PRRT because of peptide reabsorption, retention, and prolonged irradiation in the proximal tubules. We presented results of kidney functions tests in four patients before and after PRRT with 90Y-DOTATOC and 177Lu-DOTATATE, with special reference to the pathophysiology of preexisting multiple risk factors for kidney impairment. We conducted several methods routinely used in clinical practice to determine kidney function - serum creatinine, serum cystatin C, creatinine clearance (CrCl) through 24 hours of urine collection and mathematical equations for prediction of glomerular filtration rate (GFR). A very accurate measurement of kidney function (GFR and effective renal plasma flow) was done by radioactive tracers - 99Tc- diethyl triamine pentaacetic acid and 131I ortho-iodohippurate plasma clearance. Beside PRRT nephrotoxicity, patient age, preexisting kidney disease, and chronic comorbidities contribute to the risk of renal impairment. Because clinically relevant differences were assessed between calculated values and the real situation, mathematical calculation of GFR or CrCl did not seem to be appropriate to assess individual renal function precisely enough.
  Key words: Neuroendocrine Tumors; Kidney Function Tests; Glomerular Filtration Rate; Receptors, Peptide; Radiopharmaceuticals
  Read full text in PDF [Full Text]
Next article

Previous article

Table of contents

Browse all Volumes

Search all Volumes
By keywords
By authors

  Search AoO for:

  Related articles in AoO:
About Journal | Editorial Board | Editorial Policy | Instructions for Authors | Open Access | Advertising | Payed issues | Article Submission Charge | Contact
Founder, owner and publisher: Oncology Institute of Vojvodina, Serbia
Online since 1997 (Abstracts only); 2000 (Abstracts and Full text)
ISSN: 0354-7310 eISSN: 1450-9520